Clinical trials: Over Cancer
Cardiovascular Diseases, Cardiovascular Morbidity
Impact of Metabolic Health Patterns And Breast Cancer Over Time in Women
Background \& Rationale: Breast cancer (BC) is the most commonly diagnosed malignancy in women worldwide (2.1 million diagnoses in 2018, 25% of new cancer cases).
- Conditions
- Cardiovascular Diseases, Cardiovascular Morbidity, Metabolic Disease
- Trial name
- IMPACT-Women (NCT05432856)
- Testing
- Time restricted eating, nutrition education, and sedentary time reduction strategies
- Where
- 2 sites in Canada
- Volunteers
- 65 people
- Sponsor
- University of Alberta
Tuberous Sclerosis Complex
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be…
- Trial name
- NCT02962414
- Testing
- everolimus
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Hematologic Neoplasms
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion
The overall objective of this study is to collect preliminary effectiveness and safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with hematological malignancies.
- Trial name
- NCT06685848
- Testing
- Hemanext ONE system, Conventional RBCs
- Where
- 2 sites in United States, Norway
- Volunteers
- 24 people
- Sponsor
- Hemanext
Cancer
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
The rationale of the ROSY-T study is to continue to provide study treatment for patients who have participated in a parent study with osimertinib and who are continuing to derive clinical benefit from treatment at the end of such…
- Trial name
- ROSY-T (NCT05629234)
- Testing
- Osimertinib
- Where
- 27 sites in China, France and 6 more
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Colon Neoplasm, Malignant, Colo-rectal Cancer
Endoscopic Full-Thickness Resection In Colon
Endoscopic full-thickness resection (EFTR) in the colon using an over-the-scope clip (OTSC) as a closure mechanism is a recent technique that allows the endoscopic resection of colonic lesions that are poor candidates for…
- Conditions
- Colon Neoplasm, Malignant, Colo-rectal Cancer, Colonic Cancer, Colonic Adenoma
- Trial name
- EFTRICOM (NCT03803891)
- Testing
- Endoscopic full-thickness resection
- Where
- 17 sites in Spain
- Volunteers
- 65 people
- Sponsor
- Fundació Institut Germans Trias i Pujol
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer…
- Trial name
- OASIS-4 (NCT05587296)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 102 sites in Austria, Belgium and 14 more
- Volunteers
- 474 people
- Sponsor
- Bayer
Cholangiocarcinoma
A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
Primary objective: To investigate the objective response rate in patients with ROS1 or ALK over-expressed locally advanced, or metastatic intrahepatic or hilar cholangiocarcinoma receiving LDK378 Secondary objectives:The…
- Trial name
- NCT02374489
- Testing
- LDK378
- Where
- 2 sites in Taiwan
- Volunteers
- 9 people
- Sponsor
- National Health Research Institutes, Taiwan
Neoplasms
Phase I Study of BI 831266 in Patients With Advanced Solid Tumours
The main objective of this trial is to provide safety data in terms of drug-related adverse events for the recommendation of the dose for further trials in the development of BI 831266.
- Trial name
- NCT00756223
- Testing
- Arm A, Arm B
- Where
- 3 sites in Austria
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
Carcinoid Tumor, SEER Database Analysis
Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-based Analysis 2000-2022
Stage migration occurs when patients sound to have better survival or increased incidence rates at the early stage at diagnosis due to early detection of the disease.
- Conditions
- Carcinoid Tumor, SEER Database Analysis, Stage
- Trial name
- NCT07317726
- Volunteers
- 93,481 people
- Sponsor
- Suez Canal University
Myelofibrosis (MF)
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger.
- Trial name
- TRANSFORM-2 (NCT04468984)
- Testing
- Navitoclax, Ruxolitinib, Best Available Therapy (BAT)
- Where
- 229 sites in United States, Australia and 28 more
- Volunteers
- 330 people
- Sponsor
- AbbVie
Healthy
Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting Conditions
This study was designed to investigate the bioequivalence of the test and reference products when administered as single oral doses in two consecutive study periods, under fasting conditions.
- Trial name
- NCT05136521
- Testing
- Trazodone HCl - new polymer, Trazodone HCl - Contramid®
- Where
- Switzerland
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Human Papillomavirus Infection, Genital Warts
The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases
primary purpose:Evaluate the prevalence and incidence of HPV infection and related diseases in subjects. Secondary purpose:Analyze risk factors of HPV infection and related diseases.
- Trial name
- NCT02188004
- Where
- China
- Volunteers
- 4,691 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Mucositis, Neoplasms
Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis
The purpose of this study is to determine whether Oral Defense Toothpaste causes accelerated healing of chemotherapy-induced oral mucositis.
- Trial name
- TPvsM (NCT02606994)
- Testing
- Oral Defense Toothpaste, Crest Toothpaste, Magic Mouth Rinse
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Oral Defense, LLC
Breast Cancer
Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer
This research study hopes to examine the effects of Coenzyme Q10 on doxorubicin (Adriamycin) metabolism during breast cancer treatment.
- Trial name
- NCT00976131
- Testing
- CoQ10, Doxorubicin, Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Head and Neck Cancer
Magnesium Sulphate and Rocuronium in Patients Over 60
The purpose of this study is to evaluate the effects of MgSO4 administration on the pharmacodynamics of rocuronium in patients with 60 or more years of age.
- Trial name
- NCT01804205
- Testing
- Magnesium Sulfate
- Where
- Brazil
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pedro Rotava
Anemia, Cancer
A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study
The purpose of this study is to determine the safety of darbepoetin alfa beyond 16 weeks of treatment in subjects with anemia of cancer who are not receiving chemotherapy.
- Trial name
- NCT00115167
- Testing
- Darbepoetin alfa
- Volunteers
- 371 people
- Sponsor
- Amgen
Leukemia
A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors
This is a study designed to assess the safety of administration of up to 3 dose levels of eritoran in subjects undergoing or scheduled to undergo allogeneic bone marrow transplant (BMT).
- Trial name
- NCT00756912
- Testing
- E5564
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eisai Inc.
Breast Cancer
Study of Neoadjuvant Chemotherapy of Breast Cancer
The purpose of this study is to evaluate the pathological CR rate in breast and lymph nodes of a novel neoadjuvant regimen for invasive breast carcinoma.
- Trial name
- Neoadjuvant (NCT00830544)
- Testing
- Neoadjuvant chemotherapy, Chemotherapy
- Where
- Puerto Rico
- Volunteers
- 54 people
- Sponsor
- Auxilio Mutuo Cancer Center
HER2-positive
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
This is a first-in-human open-label study to evaluate the safety and tolerability, and manufacturing feasibility of anti-HER2 CAR-monocytes (CT-0525) in participants with locally advanced (unresectable) or metastatic solid tumors…
- Trial name
- NCT06254807
- Testing
- CT-0525
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Carisma Therapeutics Inc
Breast Cancer
Quality of Life in Patients With Standard External Compared to Custom-made Breast Prosthesis.
Despite improvements in surgical techniques, approximately 30% of mastectomies are still performed. Definitively or temporarily, one of the alternatives to restore a volume in the bra is the external breast prosthesis.
- Trial name
- MEAVANTI (NCT03981263)
- Testing
- MEAVANTI prothesis, Standard prothesis
- Where
- France
- Volunteers
- 64 people
- Sponsor
- University Hospital, Toulouse